Next Article in Journal
A Palladium Catalyst System for the Efficient Cross-Coupling Reaction of Aryl Bromides and Chlorides with Phenylboronic Acid: Synthesis and Biological Activity Evaluation
Next Article in Special Issue
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
Previous Article in Journal
β-Defensins in the Fight against Helicobacter pylori
Previous Article in Special Issue
Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Molecules 2017, 22(3), 417; doi:10.3390/molecules22030417

What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?

Department of Surgery and Translational Medicine, University of Florence, Florence 50134, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Wai Shiu Fred Wong
Received: 16 November 2016 / Accepted: 3 March 2017 / Published: 7 March 2017
(This article belongs to the Special Issue Nucleic Acid-based Drug)
View Full-Text   |   Download PDF [872 KB, uploaded 9 March 2017]   |  

Abstract

Despite the availability of multimodal and aggressive therapies, currently patients with skeletal sarcomas, including osteosarcoma and chondrosarcoma, often have a poor prognosis. In recent decades, advances in sequencing technology have revealed the presence of RNAs without coding potential known as non-coding RNAs (ncRNAs), which provides evidence that protein-coding genes account for only a small percentage of the entire genome. This has suggested the influence of ncRNAs during development, apoptosis and cell proliferation. The discovery of microRNAs (miRNAs) in 1993 underscored the importance of these molecules in pathological diseases such as cancer. Increasing interest in this field has allowed researchers to study the role of miRNAs in cancer progression. Regarding skeletal sarcomas, the research surrounding which miRNAs are involved in the tumourigenesis of osteosarcoma and chondrosarcoma has rapidly gained traction, including the identification of which miRNAs act as tumour suppressors and which act as oncogenes. In this review, we will summarize what is new regarding the roles of miRNAs in chondrosarcoma as well as the latest discoveries of identified miRNAs in osteosarcoma. View Full-Text
Keywords: miRNAs; osteosarcoma; chondrosarcoma; oncogene; tumour suppressor miRNAs; osteosarcoma; chondrosarcoma; oncogene; tumour suppressor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Palmini, G.; Marini, F.; Brandi, M.L. What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma? Molecules 2017, 22, 417.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top